Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

EPS and iPS Cells in Disease Research01:21

EPS and iPS Cells in Disease Research

Embryonic and induced pluripotent stem cells are excellent models for disease research because of their ability to self-renew and differentiate into most cell types. Somatic cells from a patient are isolated and reprogrammed into induced pluripotent stem cells or iPSCs. These iPSCs are later differentiated into the desired cell type, which mirrors the diseased cell of the patient. In this way, disease models have been created for investigating diseases such as Down syndrome, type I diabetes,...
iPS Cell Differentiation01:22

iPS Cell Differentiation

The ability of induced pluripotent stem cells or iPSCs to differentiate into most body cell types has stimulated repair and regenerative medicine research over the past few decades. iPSC-derived blood cells, hepatocytes, beta islet cells, cardiomyocytes, neurons, and other cell types can repair injuries or regenerate damaged tissue in diseases such as diabetes and neurodegenerative disorders.
Fibril-associated Collagen01:11

Fibril-associated Collagen

Fibril-associated collagens are a type of collagens present in the extracellular matrix with interrupted triple helices or FACIT (Fibril-associated collagens interrupted triple-helices). FACIT help connect and attach the collagen fibrils with each other as well as with other proteins of the extracellular matrix.
For example, the type II collagen fibrils in cartilage have covalently bound type IX fibril-associated collagens at regular intervals. Other types of fibril-associated collagens are...
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids01:21

Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids

Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies01:22

Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies

The key clinical manifestations of Rheumatic heart disease (RHD) include several distinct cardiac symptoms.Carditis, a hallmark of acute rheumatic fever, involves inflammation of the heart's endocardium, myocardium, and pericardium. Chronic RHD often results from recurrent episodes of carditis. Its symptoms include the following:Murmurs are caused by valvular damage, especially to the mitral and aortic valves. Mitral stenosis or regurgitation is common, with characteristic heart murmurs...
Inflammatory Bowel Disease IV: Clinical Manifestations01:20

Inflammatory Bowel Disease IV: Clinical Manifestations

Inflammatory bowel disease (IBD) encompasses two major chronic disorders—ulcerative colitis and Crohn’s disease—each characterized by relapsing episodes of gastrointestinal inflammation. Although they share certain clinical features, their patterns of involvement and manifestations differ in ways that aid diagnosis and guide management.Ulcerative ColitisUlcerative colitis is limited to the colon and rectum and involves continuous inflammation of the mucosal layer. The disease course is marked...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Author Correction: GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region.

Nature communications·2026
Same author

Perspective to precision medicine in scleroderma.

Frontiers in immunology·2024
Same author

GWAS for systemic sclerosis identifies six novel susceptibility loci including one in the Fcγ receptor region.

Nature communications·2024
Same author

Efficacy and safety of tocilizumab in Japanese patients with systemic sclerosis and associated interstitial lung disease: A subgroup analysis of a global, randomised, controlled Phase 3 trial.

Modern rheumatology·2023
Same author

Anti-nuclear autoantibodies in systemic sclerosis : News and perspectives.

Journal of scleroderma and related disorders·2022
Same author

A role for FcγRIIB in the development of murine bleomycin-induced fibrosis.

Journal of dermatological science·2021

Related Experiment Video

Updated: May 18, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Augmented ICOS expression in patients with early diffuse cutaneous systemic sclerosis.

Minoru Hasegawa1, Manabu Fujimoto, Takashi Matsushita

  • 1Department of Dermatology, Kanazawa University Graduate School of Medical Science, 13-1 Takaramachi, Kanazawa, Ishikawa 920-8641, Japan. minoruha@derma.m.kanazawa-u.ac.jp

Rheumatology (Oxford, England)
|October 2, 2012
PubMed
Summary

Inducible costimulator (ICOS) and its ligand (ICOSL) are upregulated in early diffuse cutaneous systemic sclerosis (dcSSc). Increased ICOS signaling may drive SSc pathogenesis, with soluble ICOS serving as a potential disease activity marker.

Related Experiment Videos

Last Updated: May 18, 2026

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease
04:44

Imaging Features of Systemic Sclerosis-Associated Interstitial Lung Disease

Published on: June 16, 2020

Area of Science:

  • Immunology
  • Rheumatology
  • Dermatology

Background:

  • Inducible costimulator (ICOS) and ICOS ligand (ICOSL) form a critical T-cell/antigen-presenting cell costimulatory pathway.
  • Their role in systemic sclerosis (SSc) pathogenesis, particularly early disease, remains incompletely understood.

Purpose of the Study:

  • To investigate the expression profiles of ICOS and ICOSL in patients with SSc.
  • To evaluate the association of ICOS and ICOSL with disease characteristics and clinical features.

Main Methods:

  • Flow cytometry to assess ICOS on T cells and ICOSL on B cells and macrophages in peripheral blood.
  • Immunohistochemistry and real-time PCR to analyze ICOS and ICOSL expression in lesional skin.
  • Measurement of serum soluble ICOS levels and correlation with clinical parameters.

Main Results:

  • Significantly increased ICOS expression on memory T cells and Tregs in early dcSSc patients.
  • Elevated ICOS and ICOSL in lesional skin of early dcSSc patients.
  • Enhanced IFN-γ, IL-4, and IL-17A production upon ICOS costimulation of SSc T cells.
  • Increased serum soluble ICOS levels negatively associated with ACAs and positively with CRP.

Conclusions:

  • Augmented ICOS signaling is implicated in the pathogenesis of early progressive SSc.
  • Serum soluble ICOS levels show potential as a biomarker for SSc activity and severity.